CA-HYPERICE
15.9.2022 12:02:01 CEST | Business Wire | Press release
Hyperice, a global high-performance wellness brand, today announced two new products within their heat therapy category, Venom Go and Venom 2, alongside HyperHeat™ technology for the fastest, most consistent and even distribution of heat to relieve sore, stiff muscles and promote wellness. Venom Go advances the capabilities of the Venom line further with the ability to deliver heat and vibration spot treatment in more areas, such as the neck, shoulder, upper and lower back, calf and forearm. Designed with flexibility in mind, Venom Go can be utilized in more environments than ever before, with unmatched versatility and customizations, delivering instant muscle relief wherever the body needs it most. Venom 2 is the most advanced heat and massage wrap on the market and carries on the legacy built by the original Venom line, which revolutionized the traditional heating pad for consumers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005442/en/
"The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.” -Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. (Photo: Business Wire)
“The new Venom Go is a revolutionary product for us as it widens the application of our Venom technology and addresses the need for a powerful heat and vibration solution for spot treatment,” said Jim Huether, CEO of Hyperice. “It’s been six years since the debut of heat and vibration technology from Hyperice, we’ve now significantly enhanced the Venom user experience and added our patented HyperHeat™ technology, all while staying true to the core elements of the original product that made people fall in love with it. The Venom line is one of our fastest growing product lines, and we expect this trend to continue in the U.S. and throughout the world.”
INTRODUCING VENOM GO
The Venom Go is a heat and vibration wearable that consists of a control pod that magnetically connects to an adhesive pad and is applied directly to the skin. Venom Go pads are reusable approximately 20 to 40 times each (depending on placement on body and any sweat, lotion or oil that may be on the skin) and cover 13.5 square inches, allowing users to receive direct treatment to more areas of the body than ever before. Users can select from 3 levels of heat and 3 levels of vibration via easy to use button control on the pod. Sore and stiff muscles can now receive instant treatment, with Venom Go reaching up to 113℉ (45°C) in 90 seconds after applied to the skin - or just 20 seconds prior to being applied to the skin.
The Venom Go control pod and pad weighs a mere 0.2 lbs, and holds a battery life of up to 60 minutes on a full charge, with a standard session running for 10 minutes. The Venom Go is charged via USB connection and is TSA approved for convenient use while traveling. Utilizing Bluetooth connectivity, the Venom Go is controlled via the Hyperice App, with users having the ability to sync multiple pods to deliver tailored spot treatments across different areas of the body at once for a unique heat and vibration therapy experience.
“Recovery plays a key role in performing your best every day,” said Robin Arzón, Hyperice Athlete-Investor, and Peloton Vice President of Fitness Programming. “Venom has always been a staple product in my warmup and recovery routines. Vibration and heat are both critical components in the equation. The new Venom Go allows me to be even more targeted with muscle recovery to keep me moving at my best so I can help others move at their best too.”
The introduction of the Venom Go comes on the heels of the introduction of the Normatec Go (currently only available in the US), and now provides a holistic suite of products within Hyperice’s Go series (Hypersphere Mini, Hypervolt Go 2, Vyper Go, Normatec Go). Portable and mobile adaptations of each product line offer users maximum flexibility to experience the benefits of warm up and recovery technology in more places, and at more price points, than ever before.
“With the Venom Go, users will be able to experience the same benefits they have grown to know and love in the Venom line, but in many more targeted areas for relief,” added Huether. “This product is amazing for anyone with soreness, stiffness or pain in targeted areas, and furthers our mission to help as many people as possible improve their daily lives through recovery and movement.”
INTRODUCING VENOM 2
The Venom 2, which comes in versions for the back, leg and shoulder (left or right), has more-than-doubled its treatment area, increasing the overall heating surface by 111% (94 square inches), and is encased in a new silicone surface for easier cleaning. Venom 2 delivers up to a three-hour battery life on a full charge, and heats to 131℉ (55°C) in just one minute, which is four times faster than the original Venom, and six times faster than a traditional heating pad. Users will also experience a lighter version of the Venom, as the weight drops by more than 23% from the original version, now weighing just two lbs.
“Heat therapy is such a critical component of my routine, from preparing for a game and getting my shoulder loose, to treating sore muscles in my arm between practices,” said Patrick Mahomes, Hyperice Athlete-Investor and Super Bowl Champion. “From pregame, to the training facility and home, the Venom line allows me to optimize my performance. The new Venom 2 improves the experience and I know will be a popular tool in the locker room.”
“As a footballer, I need to ensure that my body is ready to endure the rigors that come with a 90-minute match,” said Erling Haaland, Hyperice Athlete-Investor and global footballer. “Heat therapy is very important in ensuring my body is properly prepared and ready to go ahead of training or kickoff, and equally important in the time between match-days. I’m always looking for ways to give myself a competitive edge, and with Venom 2’s heating time, I feel the benefits quicker than ever before, and can be ready to take the pitch faster with my body ready to go.”
Through Bluetooth® connectivity, the Venom 2 is controlled via the Hyperice App, unlocking more routines to maximize and customize time, heat and vibration while using the device.
HYPERHEAT™ TECHNOLOGY
With the launch of Venom Go and the Venom 2, Hyperice also introduces their new HyperHeat™ technology which delivers a faster, more consistent distribution of heat across a greater surface area, allowing for a more premium experience for users.
“In 2015 we were getting requests from NBA players for a product that could heat the body pregame and keep the body warm when they came out of the game. Our answer was the Venom, the first heat and vibration wearable device, released in 2017,” said Anthony Katz, Hyperice Founder. “Over the past five years, the user base for the Venom has expanded far beyond performance athletes to everyday people who use the Venom to manage pain and soreness. The Venom 2 is a complete redesign and upgrade from the original model- every aspect of the product and experience have been improved.“
The Venom Go ($149; £159; €175) and Venom 2 line ($249; £269; €299) are available in North America as well as globally across all countries and regions where Hyperice is sold. For more information, please visit hyperice.com country-specific sites.
About Hyperice
Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005442/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 03:00:00 CEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202627.5.2026 23:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy demonstrated statistically significant overall survival benefit with an unprecedented seven-month improvement in first-line HER2+ GEAOral presentation at ASCO highlights benefit regardless of PD-L1 status, including in PD-L1 <1% BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei Univ
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 17:22:00 CEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 16:00:00 CEST | Press release
As buyers face tighter budgets, Capchase helps technology companies close more deals faster with AI-enabled instant financing Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks wi
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 15:00:00 CEST | Press release
Annual run-rate revenue more than tripled year-over-year; new CostBench benchmark shows ClickHouse Cloud at 23x better cost-performance than the nearest cloud data warehouse ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
